Generated June 2026 from current fund data.
Overview
OMAH and SCHD represent two fundamentally different philosophies for dividend investors. OMAH is a newly launched, actively managed options-income ETF that owns Berkshire Hathaway Class B shares exclusively and uses systematic call-writing to generate a 15% distribution target. SCHD is an established, passive dividend tracker holding 100 large-cap U.S. stocks screened for consistent dividend growth and fundamental strength. The key distinction: OMAH chases yield through derivatives on a single stock; SCHD pursues stable income through broad diversification.
How they differ
OMAH's strategy hinges on extracting monthly cash flow from Berkshire Hathaway by selling covered calls against its core holding, targeting 14.99% annual yield. SCHD simply tracks a basket of 100 dividend-payers and pays distributions quarterly at 3.16%. That 11.8 percentage-point yield gap is the most obvious difference, but it comes with structural tradeoffs: OMAH's call-writing limits upside capture if Berkshire rallies significantly, while SCHD offers pure equity exposure to a diversified, fundamentally screened dividend cohort. Expenses tell a second story—SCHD's 0.06% fee is negligible compared to OMAH's 0.95%, a meaningful drag on net returns if yield compression occurs. Third, OMAH arrived in March 2025 with $831M in assets, while SCHD has $95.2B and nearly 14 years of track record, a meaningful difference in proven viability and fund stability.
Who each is best for
OMAH: Fits investors seeking monthly income and willing to accept single-stock concentration and options-overlay complexity in exchange for a high current distribution yield; suits tactical allocations where temporary elevated yield matters more than diversification or long-term capital appreciation.
SCHD: Fits income-focused investors who value broad exposure to proven dividend growers, lower fees, and quarterly predictability; designed for buy-and-hold allocations where steady compound growth of distributions and capital takes priority over maximum near-term yield.
Key risks to know
- NAV erosion at high yields. OMAH's 14.99% distribution targeting suggests reliance on return-of-capital treatment and synthetic income generation to sustain distributions; if Berkshire's underlying returns fall short or call-writing revenue declines, NAV could erode over time even if distributions hold.
- Single-name concentration and call-writing cap. OMAH holds only Berkshire Hathaway, eliminating diversification benefits; short calls also cap upside if the stock rallies sharply, converting gains into capped returns and potentially forcing assignment at prices below market value.
- Fund inception risk. OMAH launched in March 2025 with no operating history or stress-test data; early-stage active options strategies can struggle when volatility spikes, funding flows reverse, or underlying assumptions (Berkshire dividend policy, call premium availability) shift unexpectedly.
- Equity beta and market sensitivity. OMAH's beta of 0.3287 reflects call-writing dampening; in a rising market, that lower beta becomes a structural drag on absolute returns relative to broader equity indices.
- Tracking divergence in SCHD. SCHD's passive tracking can diverge from the index if cash drag, rebalancing costs, or dividend reinvestment timing lag the benchmark, though its massive AUM and tight expense ratio minimize this risk.
Bottom line
If you need monthly income today and can tolerate single-stock exposure and options complexity, OMAH's 15% yield is genuinely compelling—but its brand-new track record and structural yield concentration demand scrutiny. If you prioritize diversification, proven performance, low fees, and sustainable dividend growth over maximum current payout, SCHD's simplicity and $95.2B in assets represent the opposite extreme. Past performance doesn't predict future results, especially for a strategy as new as OMAH's options overlay.
AI-generated analysis for educational purposes only. Verify important details independently; past performance does not guarantee future results.